Some providers featured on this site may compensate us. This may affect the order and placement of listings but does not influence our editorial ratings or reviews.
Treatments Hub

Verified prices

All verified prices
Guide6 min read

Do You Qualify for GLP-1 Weight Loss Medication?

Not everyone is eligible for semaglutide or tirzepatide. Here's a clear look at the medical criteria, BMI requirements, and conditions that affect eligibility.

Updated September 15, 2026

Medically reviewed on

How we review

BMI Requirements for Eligibility

Clipboard with a blank checklist, stethoscope, blood-pressure cuff and tape measure on a clinic table, the eligibility check for GLP-1 weight-loss medication
The FDA-approved criteria for weight loss medications like Wegovy and Zepbound require a BMI of 30 or higher (classified as obesity) or a BMI of 27 or higher with at least one weight-related health condition such as type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnea. Many telehealth providers follow these same guidelines, though some may have slightly different thresholds for compounded medications. Your provider will calculate your BMI during the initial evaluation and determine whether you meet the clinical criteria.

Our top 2 picks

Our two recommended GLP-1 providers, shown with the same verified pricing and ratings as our full comparison.

Our Top Pick
1
embody logo

Exceptional

9.8out of 10

Compounded GLP-1 from $49/month; not FDA-approved, free expedited delivery

Free expedited deliveryNo hidden fees
  • Compounded semaglutide ($49/mo) and tirzepatide ($99/mo) as shown on the homepage, Nov 16, 2026; not FDA-approved
  • Online intake, then a prescriber review by OpenLoop Health, a network of US-licensed doctors
  • Free expedited delivery (embody's words); the Terms do not guarantee a delivery timeline
  • No insurance required, no clinic visits; cancel at least 72 hours before the next billing date

from $49/month

Doctor-prescribed compounded GLP-1 treatment, not FDA-approved: semaglutide shown at $49/month and tirzepatide at $99/month on embody's homepage (Nov 16, 2026), no insurance required.

Read full embody review
2
altRx logo

Excellent

9.4out of 10

Most Comprehensive GLP-1 Medication Access

Transparent pricingNo insurance required
  • Compounded GLP-1 from $89/mo, GLP-1 + GIP from $149/mo
  • Brand-name options too: Zepbound and Wegovy
  • Clinician-guided - physician, PA, or nurse practitioner
  • Free shipping (about 5-7 days)

from $89/month

Affordable GLP-1 program from $89/month - compounded semaglutide and tirzepatide plus brand-name options - with clinician-guided, self-pay care and no insurance required.

Read full altRx review

Medical Conditions That May Disqualify You

Certain health conditions make GLP-1 medications unsafe. These include a personal or family history of medullary thyroid carcinoma (MTC), a history of multiple endocrine neoplasia syndrome type 2 (MEN 2), a history of pancreatitis, and known hypersensitivity to semaglutide or tirzepatide.

Patients with severe gastrointestinal disorders, including gastroparesis, may also be advised against these medications. Pregnancy and breastfeeding are absolute contraindications - you should stop the medication at least two months before planning to conceive.

Age and Other Considerations

Most providers prescribe GLP-1 medications to adults aged 18 and older. Wegovy has FDA approval for adolescents aged 12 and up with obesity, but this is typically managed through in-person pediatric endocrinologists rather than telehealth platforms.

For older adults, providers will consider factors like kidney function, existing medications, and overall health status. There is no strict upper age limit, but a thorough medical evaluation becomes especially important for patients over 65.

Shop GLP-1 plans by product

The lowest published plans - cheapest first, conditions under each price.

Medications That May Interact

GLP-1 medications can interact with other drugs, particularly insulin and sulfonylureas (which may increase the risk of hypoglycemia when combined). Because GLP-1 agonists slow gastric emptying, they can also affect the absorption of oral medications.

Your provider will review your full medication list during the evaluation process. If you take oral birth control, blood thinners, or thyroid medication, discuss timing and potential interactions with your provider before starting treatment.

Learn more about potential side effects in our semaglutide side effects guide.

What To Know Before Starting GLP-1 Treatment

Before starting GLP-1 treatment, it's important to understand a few key things. These medications require a prescription from a licensed clinician and aren't suitable for everyone. Some people may experience side effects, especially during the first few weeks as the body adjusts.

GLP-1s also tend to work best when combined with basic lifestyle habits like balanced nutrition and regular physical activity.

That's why choosing a provider that offers proper medical screening and ongoing follow-up support is essential for both safety and long-term success.

Woman preparing GLP-1 weight loss injection

The Evaluation Process

Most telehealth providers follow a straightforward process: you complete a detailed health questionnaire, provide your medical history and current medications, and have a consultation with a licensed provider (usually via video or asynchronous message). Some providers require recent lab work, while others may order labs as part of their program.

The evaluation typically takes one to three days, and if approved, your medication can be shipped within a week. For tips on choosing the right platform, read our guide on selecting a telehealth provider.

Ready to compare weight loss providers?

See how top providers stack up on pricing, medical support, and treatment options.

Medical disclaimer

This page is general information about GLP-1 weight-loss medications such as semaglutide and tirzepatide, published to help you compare services. It is not medical advice, it does not create a doctor-patient relationship, and it is not a substitute for a consultation with a licensed clinician who knows your history. Treatments Hub is not a medical provider, pharmacy or clinic and does not prescribe, sell or dispense medication. Do not start, stop or change any treatment because of something you read here, and do not delay seeking care; in an emergency call 911.

Semaglutide and tirzepatide carry an FDA boxed warning about thyroid C-cell tumours seen in rodents and are not for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2, nor for use in pregnancy. Compounded versions sold by telehealth providers are prepared by state-licensed pharmacies and are not FDA-approved products. Where a review or post on this page mentions weight lost, that is one person's result and is not typical; results vary widely.

Medical and scientific statements on this site are checked against the sources linked on the page by our medical content reviewer, who does not choose providers or set prices. Prices, plans and customer reviews are each provider's published figures and customers' own words on the dates stated. We may earn a commission from provider links. The full medical and advertising disclaimer explains all of this in detail.

Sources & medical references

Treatment facts on this page are grounded in regulatory guidance and peer-reviewed research. Pricing and plan details come from each provider's published information. This content is for information only and is not medical advice - always consult a licensed clinician before starting treatment.

  1. 1.Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial) - New England Journal of Medicine, 2021
  2. 2.Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 trial) - New England Journal of Medicine, 2022
  3. 3.FDA Approves New Drug Treatment for Chronic Weight Management (semaglutide / Wegovy) - U.S. Food & Drug Administration, 2021
  4. 4.FDA Approves New Medication for Chronic Weight Management (tirzepatide / Zepbound) - U.S. Food & Drug Administration, 2023
  5. 5.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss - U.S. Food & Drug Administration
  6. 6.Human Drug Compounding (503A pharmacy standards) - U.S. Food & Drug Administration
  7. 7.Semaglutide Injection - drug information - MedlinePlus, U.S. National Library of Medicine (NIH)